«

»

May 04

Long–term results from the Study of Heart and Renal Protection (SHARP)

Long–term results from the Study of Heart and Renal Protection (SHARP) have shown that for patients with chronic kidney disease (CKD), lowering LDL cholesterol with a combination of simvastatin and ezetimibe may not curb the progression of kidney disease to end–stage renal disease (ESRD). The findings are published May 1 in the Journal of the American Society of Nephrology.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>